Actively Recruiting
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
Led by Shu Wang · Updated on 2024-11-25
1166
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The survival rate of patients with pathological complete response (pCR) after neoadjuvant therapy was significantly better than that of patients with tumor residue, that is, non-pCR patients. Therefore, studies have confirmed that intensive adjuvant therapy for patients with non-pCR after neoadjuvant chemotherapy can further improve the survival of this population. Previous studies have given capecitabine treatment to such patients as standard. However, it is unknown whether capecitabine intensification still has the same status under the premise that most patients receive immunotherapy at the neoadjuvant stage; Whether there are differences in the efficacy and safety of capecitabine standard 6-8 cycle intensive regimen and capecitabine metronomic chemotherapy are practical problems encountered in clinical practice. This study explored the efficacy and safety of 6-8 cycles of full dose capecitabine intensive therapy compared with 1-year capecitabine metronomic chemotherapy in patients with T2 and above and/or lymph node positive early triple negative breast cancer who still had invasive tumor after neoadjuvant therapy.
CONDITIONS
Official Title
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with triple negative breast cancer diagnosed by biopsy at Peking University People's Hospital
- Clinical stages before treatment were T1-T4, N0-N3, M0
- Received treatment and surgery at Peking University People's Hospital with hospitalization records
- Neoadjuvant chemotherapy is allowed without limit; immunotherapy allowed in neoadjuvant and/or adjuvant treatment
- Postoperative pathology confirms residual invasive breast cancer in breast and/or axillary lymph nodes
- Signed and agreed to participate in the PKUPH breast disease cohort study
You will not qualify if you...
- Missing clinical or pathological data such as imaging or pathology reports
- Presence of metastatic or bilateral breast cancer
- Failure to perform radical surgery
- Pathogenic or possibly pathogenic BRCA mutations with postoperative intensive PARP inhibitor treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
yuan peng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here